Format

Send to

Choose Destination
Biol Blood Marrow Transplant. 2017 Sep;23(9):1473-1477. doi: 10.1016/j.bbmt.2017.05.020. Epub 2017 May 22.

Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain Amyloidosis.

Author information

1
Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
2
Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, Tennessee.
3
Division of Biostatistics and Quantitative Sciences, Vanderbilt University Medical Center, Nashville, Tennessee.
4
Division of Nephrology, Vanderbilt University Medical Center, Nashville, Tennessee.
5
Division of Gastroenterology, Vanderbilt University Medical Center, Nashville, Tennessee.
6
Division of Cardiology, Vanderbilt University Medical Center, Nashville, Tennessee.
7
Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, Tennessee. Electronic address: robert.f.cornell@vanderbilt.edu.

Abstract

Light chain amyloidosis (AL) results in tissue deposition of misfolded proteins, causing organ dysfunction. In an era of modern therapies, such as bortezomib, reassessment of the benefit of autologous hematopoietic cell transplantation (AHCT) should be considered. In this study, we compared outcomes between patients with AL receiving chemotherapy alone (CT) and those undergoing AHCT. Seventy-four patients with AL were analyzed retrospectively. Two cohorts of patients were studied, those receiving CT (n = 31) and those undergoing AHCT (n = 43). Of the 43 patients in the AHCT cohort, 29 received induction chemotherapy before AHCT, whereas 14 proceeded straight to AHCT without induction therapy. Compared with the CT cohort, patients in the AHCT cohort were younger and had higher ejection fractions, lower brain natriuretic peptide levels, and more severe proteinuria. The majority (87%) of patients in the CT cohort received bortezomib-based treatment. Transplantation-related mortality (TRM) was 7%. Patients receiving AHCT were more likely to achieve complete or very good partial response (P = .048). The median progression-free survival (PFS) and overall survival (OS) were superior in the AHCT cohort (not reached versus 9 months; P < .01 and 74 months versus 8 months; P = .03, respectively). Multivariable analysis demonstrated that improved PFS (hazard ratio, 3.86; 95% confidence interval [CI] 1.3 to 11.5; P = .02) and OS (hazard ratio, 5.6; 95% CI, 1.9 to 16; P < .001) were associated with use of AHCT compared with CT. Patients in the AHCT cohort had deeper and longer durations of response, with superior PFS and OS, compared with those in the CT cohort. Despite the limitations of this study, AHCT should be considered for eligible patients with AL at experienced transplantation centers that can offer this therapy with a low risk of TRM.

KEYWORDS:

Bortezomib; Light chain amyloidosis; Organ response, chemotherapy; Transplantation

PMID:
28546074
DOI:
10.1016/j.bbmt.2017.05.020
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center